Fullscript has a new owner. Altas Partners and L Catterton bought a majority stake in the health-and-wellness platform. The sellers were prior backers HGGC and Snapdragon Capital Partners, and both buyers confirmed the deal in a Sept. 10 filing.
The company runs the plumbing of the practitioner-dispensing trade. Doctors, dietitians and other providers write supplement protocols through its software. Patients order the products. Fullscript handles fulfillment and tracks whether people actually take what they were prescribed. The model long ago outgrew the company’s start as a plain online dispensary, and it now reaches tens of thousands of practices across North America.
HGGC and Snapdragon are cashing out after a multiyear hold. They backed Fullscript through its combination with Emerson Ecologics and a national push into whole-person care. Trade coverage of the sale, including a breakdown from private-equity outlet PE Hub, read the exit as a clean handoff to two bigger sponsors with deeper consumer-health portfolios.
The buyers bring different strengths. Altas Partners favors long holds and knows healthcare services well. L Catterton, the consumer specialist with ties to LVMH, adds brand and retail muscle that fits a direct-to-practitioner supplement business. What they share is an appetite for companies that earn money on repeat orders. Fullscript is built on exactly that.
Joele Frank, Wilkinson Brimmer Katcher advised HGGC on the sale. The firm ran press for the outgoing majority owner and set the timing so the seller’s exit and the incoming investment landed as one orderly move rather than a messy scramble.
Neither side put a price on the table, which is normal when a private company changes private hands. What the parties did signal is continuity. Management stays. The provider-facing product stays. The new sponsors want to fund expansion, not break the business into parts.
There’s a bigger story in the software layer of the supplement trade. Brands used to compete on formulation and price. Now the platform that carries a practitioner’s recommendation to a patient’s doorstep skims a durable cut of every sale, and Fullscript owns that layer. It’s why the company reads to sponsors less like a retailer and more like infrastructure. For the wellness industry, the sale is one more sign of capital pooling around the companies that control distribution.
Practitioners are unlikely to notice much day to day. The pitch to them stays the same: one place to recommend, sell and monitor supplements without juggling vendors. Deeper-pocketed owners, though, can pay for the sales team, the data tools and the bolt-on acquisitions that widen the moat. Rivals such as Thorne and other dispensing platforms now face a Fullscript with more room to spend.
Closing still hinges on customary conditions and approvals. Once it settles, Fullscript moves from a mid-market ownership group to two firms with the balance sheets to chase bigger deals of their own. How supplement dispensing consolidates over the next few years may turn on what they do with it.